Complications Following Non-Surgical Aesthetic Treatments in HIV+ Patients Receiving Antiretroviral Therapy: A 12-Years Experience
Source abstract
Abstract
Since the advent of HIV antiretroviral therapies at the end of the 20th century, the morbidity and mortality rates associated with HIV infection have decreased dramatically. Unfortunately, these benefits are associated with substantial morphologic changes in the body, such as abnormal fat distribution with peripheral lipohypertrophy and facial lipoatrophy. Facial wasting is considered the major stigma for HIV–infected people and may result in reduced antiretroviral adherence. Patients suffering from the stigmata of HIV infection can benefit from non-surgical aesthetic treatments performed with fillers or lipolytic agents that provide a quick and reliable service for facial rejuvenation, with high patient satisfaction and a low risk of complications. In the present paper, a retrospective analysis of complications following non-surgical aesthetic treatments (calcium hydroxyapatite-based filler, hyaluronic acid filler, polyacrylamide hydrogel filler and dehoxycholic acid injections), in a cohort of 116 consecutive HIV+ patients, treated over a period of 12 years, was performed. With the exception of the tardive swelling reported after calcium hydroxyapatite injections, complications were recorded just after polyacrylamide hydrogel treatment as small, palpable, nonvisible nodules or aseptic abscess. Our experience is consistent with those already published in the literature and the complication rate seems to be comparable to non-infected patients.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Facial Rejuvenation and Surgery Techniques · Syphilis Diagnosis and Treatment · Herpesvirus Infections and Treatments
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Private Practice, 80136 Naples, Italy
Private Practice, 81055 Santa Maria Capua Vetere, Italy
Maxillofacial Surgery Unit, Multidisciplinary Department of Medical-Surgical and Dental Specialities, University of Campania “Luigi Vanvitelli”, 80138 Naples, Italy
General Surgery Unit, Department of Advanced Medical and Surgical Sciences, University of Campania “Luigi Vanvitelli”, Piazza Miraglia, 80138 Naples, Italy
Private Practice, 70125 Bari, Italy
References (39)
Show source-provided references
1. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an in-hibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group10.1056/NEJM199512073332303 ↗
2. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimetre or less. AIDS Clinical Trials Group 320 Study Team10.1056/NEJM199709113371101 ↗
3. Redefining lipodystrophy syndrome: Risks and impact on clinical decision making10.1097/01.qai.0000167478.28051.3a ↗
4. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in pa-tients receiving HIV protease inhibitors10.1097/00002030-199807000-00003 ↗
5. Failure to maintain long-term adherence to highly active antiretroviral therapy: The role of lipodystrophy10.1097/00002030-200112070-00012 ↗
6. Surgical Algorithm for Management of HIV Lipodystrophy10.1097/01.prs.0000267341.14550.a7 ↗
7. Autologous fat transfer for face rejuvenation with tumescent tech-nique fat harvesting and saline washing: A report of 215 cases10.1159/000338574 ↗
8. The role of lipofilling in reconstructions with dermal regeneration template: Clinical and histological assessment
9. Comparison between lipofilling and a non resorbable filler for facial wasting rehabil-itation in HIV+ patients10.1097/SCS.0b013e31822e5cf8 ↗
10. Is buffalo hump fat the perfect filler for facial wasting rehabilitation? Reflection on three cases10.1007/s00238-011-0581-2 ↗
11. (2021, January 20). American Society for Aesthetic Plastic Surgery: Cosmetic Surgery National Data Bank Statistics for 2016. Available online: https://www.surgery.org/sites/default/files/ASAPS-Stats2016-11-12.pdf.
12. Skin Remodeling Using Hyaluronic Acid Filler Injections in Photo-Aged Faces10.1097/DSS.0000000000000659 ↗
13. Scarano, A., Sbarbati, A., Amore, R., Iorio, E.L., Ferraro, G., Marchetti, M., and Amuso, D. (2020). The role of hyaluronic acid and amino acid against the aging of the human skin: A clinical and histological study. J. Cosmet. Dermatol.10.1111/jocd.13811 ↗
14. Rhinofilling with hyaluronic acid thought as a cartilage graft10.1016/j.jcms.2020.01.008 ↗
15. Semipermanent volumization by an absorbable filler: Onlay injection technique to the bone10.1097/GOX.0b013e31828c66b0 ↗
16. Clinical, histologic, and electron microscopic findings after injection of a calcium hydroxylapatite filler10.1080/147641704100003048 ↗
17. Human Histology and Persistence of Various Injectable Filler Substances for Soft Tissue Augmentation10.1007/s00266-020-01827-7 ↗
18. A Systematic Review of Permanent and Semipermanent Dermal Fillers for HIV-Associated Facial Lipoatrophy10.1089/apc.2008.0230 ↗
19. An adipocitolitic aqueous micro-gelatinous solution for buffalo hump deformity reduction
20. Complications of minimally invasive cosmetic procedures: Prevention and management10.4103/0974-2077.99451 ↗
21. HIV-associated facial lipoatrophy
22. Safety and efficacy of one-step rehabilitation of human immunodeficiency virus-related facial lipoatrophy using an injectable calcium hydroxylapatite dermal filler10.1111/dsu.12358 ↗
23. Polyacrylamide gel for facial wasting rehabilitation: How many milliliters per ses-sion?10.1007/s00266-011-9757-1 ↗
24. A facial marker in facial wasting rehabilitation
25. Human Immunodeficiency Virus–Related Lipoatrophy of the Face: Where Should We Have to Fill?10.1097/PRS.0b013e3182131e38 ↗
26. 5-Year Study of a Polyacrylamide Hydrogel-Based Filler for Rehabilitation of HIV-Related Facial Lipoatrophy10.1093/asj/sjv036 ↗
27. Polyacrylamide hydrogel injection in the management of human immunodeficiency virus-related facial lipoatrophy: A 2-year clinical experience10.1097/01.prs.0000298108.46379.15 ↗
28. Long-term efficacy and safety of polyacrylamide hydrogel injection in the treatment of human immunodeficiency virus-related facial lipoatrophy: A 5-year follow-up10.1097/PRS.0b013e3182362142 ↗
29. A 5-year assessment of safety and aesthetic results after facial soft-tissue augmentation with poly-acrylamide hydrogel (Aquamid): A prospective multicenter study of 251 patients10.1097/PRS.0b013e3181d18158 ↗
30. Unacceptable Results with an Accepted Soft Tissue Filler: Polyacrylamide Hydrogel10.1007/s00266-009-9359-3 ↗
31. Polyacrylamide Gel Injection for Treatment of Human Immunodeficiency Virus-Associated Facial Lipoatrophy: 18 Months Follow-Up10.1111/j.1524-4725.2011.02131.x ↗
32. Four-Year Safety with Polyacrylamide Hydrogel to Correct Antiretroviral-Related Facial Lipoatrophy10.1089/aid.2008.0230 ↗
33. Ten-Year Safety with Polyacrylamide Gel Used to Correct Facial Lipoatrophy in HIV-Infected Patients10.1089/aid.2015.0004 ↗
34. A unique late complication with the use of calcium hydroxylapatite filler in facial lipoatrophy rehabilitation10.4103/2347-9264.143563 ↗
35. Delayed-Onset Nodules to Differentially Crosslinked Hyaluronic Acids: Comparative Incidence and Risk Assessment10.1097/DSS.0000000000001814 ↗
36. “Bullfrog neck,” a unique morphologic trait in HIV lipodystrophy: Case series and review of the lit-erature10.1001/archdermatol.2010.341 ↗
37. Remodeling the neck and the lower jaw with dehoxycholate injections
38. A CE-Marked Drug Used for Localized Adiposity Reduction: A 4-Year Experience10.1093/asj/sju082 ↗
39. Late Onset Complications Secondary to Polyacrylamide Hydrogel-Based Filler for Re-habilitation of HIV-Related Facial Lipoatropy10.1093/asj/sjy226 ↗